Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued
ANDA Sponsor And AstraZeneca Disagreed On Chances Of Settlement
Executive Summary
In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.
You may also be interested in...
IP Divisions In Indian Courts: Will Pharma See Expediated Adjudication?
A second court in India establishes an intellectual property division to consider IPR matters and notifies rules following the dissolution of the Intellectual Property Appellate Board in 2021. Legal experts outline what that may mean for the efficiency and quality of IPR adjudications.
IP Divisions In Indian Courts: Will Pharma See Expediated Adjudication?
A second court in India establishes an intellectual property division to consider IPR matters and notifies rules following the dissolution of the Intellectual Property Appellate Board in 2021. Legal experts outline what that may mean for the efficiency and quality of IPR adjudications.
Zydus Knocked Back On Farxiga In US As Brand Continues To Grow
Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.